Everyone should listen to a @BraunMDPhD talk at least quarterly (doctor's orders!)
Fantastic talk focused on personalized cancer vaccines in RCC. Looking forward to the results of INTerpath-004!
#ESMO26@OncoAlert
👉We deeply mourn the loss of our dear friend, loving big sister, co-fellow, world expert, the brilliant light, amazing all-time Dr .@rachnatshroff | May she rest in peace. May her wonderful legacy carry on forever, may we never forget @rachnatshroff 🙏
https://t.co/K8Z9l9yFsm
Congratulations @montypal on the KCA Eugene P. Schonfeld Award! 🎉 An extraordinary mentor, leader, and kidney cancer researcher whose work has changed how we treat RCC, and who generously lifts up colleagues worldwide. Thoroughly deserved. #IKCSNA26#kidneycancer
Pick any medical specialty other than your own. Who’s the most famous physician in it? You probably can’t name one.
Almost none of us will be known outside our field, and even those who achieve real professional fame are mostly forgotten within a few decades.
Fame is a poor reason to devote your life to medicine. The work itself matters more: caring for patients, discovering new knowledge, and teaching the next generation.
Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber
1) Dr. Nazli Dizman @NazliDizman
2) Dr. Brian Russell @brian_russell39
3) Dr. Hamid Emamekhoo @HamidEmamekhoo
4) Pr. Neeraj Agarwal @neerajaiims
They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology.
Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc
We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands.
Welcome to @CityOfBoston and @DanaFarber!
JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯
Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma.
For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy.
Personalized cancer vaccines are moving from promise to reality.
Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏
Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (https://t.co/BdbKJqMKOw)
https://t.co/Akd0XQt3ml
Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims@VanAllenLab@nikolausschultz https://t.co/BKJfuHRX6f
🎉Incredibly proud of this publication and grateful for the leadership of @salvolarosa@BataiKen@PavlosMsaouel and other contributors who made this important research possible. Our paper is out today with FREE access!
🔗https://t.co/dJc6aQ40wk